CEA, Cyfra21‐1, and NSE were the most commonly measured within 3 months before first diagnosis with approximately 65% in NSCLC and 80% in SCLC, and ProGRP had the lowest utilization (around 30%). This evidence concerns the gene ENO2 and small cell lung carcinoma.